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There are no clearly established indications for testos-terone therapy for women. Nonetheless, clinicians
have treated women with testosterone for decades, with
the intention of alleviating a variety of symptoms, with
uncertain benefits and risks. In most countries, testos-
terone therapy is prescribed off-label such that women
are using either testosterone formulations approved for
men with dose modification, or compounded therapies.
Because of these issues, there is a compelling case for a
global consensus Position Statement on testosterone
therapy for women based on the available evidence from
placebo/comparator randomized controlled trials (RCTs).
This Position Statement was developed, by consensus
between the participating organizations, to inform health
care professionals of the known benefits and potential
risks of testosterone therapy for women. The aims were
to provide clear guidance as to which women might
benefit from testosterone therapy, to identify symptoms,
signs, and conditions for which evidence does not sup-
port the prescribing of testosterone, to explore areas of
uncertainty, and to identify any prescribing practices that
have the potential to cause harm.
Methods
A Task Force of representatives of leading societies, whose
international memberships include clinicians assessing and
managing sex steroid therapy for women, was established. The
Task Force agreed on the issues that needed to be addressed,
after which a systematic review and meta-analysis of the ben-
efits and risks of testosterone therapy for women were con-
ducted (1). The Task Force then met on 17May 2019 in Berlin,
Germany, and drafted this consensus position statement.
Recommendations regarding the benefits and risks of tes-
tosterone therapy are based on findings from blinded placebo/
comparator RCTs, of at least 12 weeks duration for which data
were available for inclusion in meta-analyses (1). The findings
are reported with Levels of evidence and Grades of Recom-
mendations (2). Clinical practice recommendations are agreed
expert opinions of the panel. Through constructive discussion,
unanimous consensus agreement was reached on all the Expert
Opinion recommendations included here.
Recommendations
I. Measurement of testosterone, female sexual
dysfunction, and endogenous androgen levels
(1) Recommendations pertaining to the measurement
of circulating testosterone in women
(a) Testosterone may act directly via the andro-
gen receptor/nongenomic androgenic action,
or by reduction to the more potent androgen
dihydrotestosterone and/or aromatization to
estradiol and their metabolites.
(b) Testosterone concentrations decline during
the reproductive years (3, 4) (Level IIB).
(c) Testosterone concentrations appear to be
maintained in women beyond the age of 65
years, but whether this confers a benefit is yet
to be understood (3, 5) (Level IIB).
(d) Total testosterone can be measured with high
accuracy and reproducibility using liquid/gas
chromatography and tandem mass spec-
trometry assays (6) (Grade B).
(e) Direct assays for the measurement of total and
free testosterone are highly unreliable in the
female range (6, 7) (Grade A).
( f) Reference laboratories should be “harmo-
nized” with biological standards in coordina-
tion with the US Centers for Disease Control
and Prevention (8) (Expert Opinion).
(g) Measurement of testosterone using direct
assays in clinical practice is appropriate, if
liquid/gas chromatography and tandem mass
spectrometry assay is not available, to exclude
high baseline concentrations and also to ex-
clude supraphysiological concentrations dur-
ing treatment (Expert Opinion).
(h) Current research into testosterone physiology
and clinical effects should mainly focus on
measuring total testosterone as the main
biomarker rather than “free” testosterone
because evidence that “free” testosterone is
the biologically active testosterone fraction is
lacking (9) (Expert Opinion).
(2) Recommendations for the terminology for female
sexual dysfunction (FSD)
(a) Hypoactive sexual desire disorder/dysfunction
(HSDD) and female sexual arousal disorder
(FSAD) are distinct conditions that should be
categorized separately when considering the
impact of androgens on their clinical presen-
tation and response to treatment (Grade B).
(b) Although HSDD and FSAD overlap, they
have distinct etiologies, risk factors, clinical
features, and responses to psychological and
biological interventions (10) (Grade B).
(c) Traditional specifiers (i.e., lifelong vs ac-
quired; generalized vs situational) should be
retained and used to further categorize and
stratify treatments forHSDD and other female
sexual disorders/dysfunctions (10).
(d) The diagnosis of HSDD in clinical practice
should be based on thorough clinical assess-
ment (11) guided by available diagnostic cri-
teria such as the International Society for the
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Study of Women’s Sexual Health (12, 13) or
the International Classification of Diseases,
11th edition (14) (Expert Opinion).
(3) Recommendations pertaining to the associations
between endogenous androgen concentrations
and female sexual function
(a) The associations between endogenous androgen
concentrations and sexual function in women
remain uncertain because of issues relating to the
sensitivity and specificity of androgen assays in
some studies and insufficient data (Insufficient).
(b) The physiology of androgens is complex be-
cause of their conversion in tissues and pos-
sible intracrine metabolism in multiple tissues
(Insufficient).
(c) No cutoff blood level can be used for any
measured circulating androgen to differentiate
women with and without sexual dysfunction
(15) (Grade C).
II. Recommendations regarding systemic
testosterone therapy for postmenopausal women,
in doses that approximate physiological
testosterone concentrations for premenopausal
women, based on findings from meta-analyses of
placebo/comparator-controlled RCTs (1, 16)
There are insufficient data to make any recom-
mendations regarding the use of testosterone in pre-
menopausal women for treatment of sexual function or
any other outcome (Insufficient).
(4) Recommendations regarding testosterone treat-
ment of naturally or surgically postmenopausal
women with HSDD, with/or without concurrent
estrogen therapy
(a) Testosterone therapy, in doses that approxi-
mate physiological testosterone concentrations
for premenopausal women, exerts a beneficial
effect on sexual function including increases,
above the effects of placebo/comparator ther-
apy, of an average of one satisfying sexual event
per month, and increases in the subdomains
of sexual desire, arousal, orgasmic function,
pleasure, and sexual responsiveness, together
with a reduction in sexual concerns including
sexual distress (Level I, Grade A).
(b) Because the majority of studies reporting on
sexual function recruited women assessed as
having HSDD or generalized FSD, these rec-
ommendations cannot be generalized to other
subtypes of FSD or women without sexual
dysfunction (Expert Opinion).
(c) The recommendations of 4(a) do not apply to
injectables, pellets, or formulations that result
in supraphysiological blood concentrations
of testosterone, or compounded preparations
(Expert Opinion).
(5) Recommendations regarding the effects of tes-
tosterone on wellbeing, mood, and cognition in
postmenopausal women
(a) There is insufficient evidence to support the
use of testosterone to enhance cognitive per-
formance, or to delay cognitive decline, in
postmenopausal women (Insufficient).
(b) Available data show no effect of testosterone
therapy on general wellbeing (Level I, Grade A).
(c) Testosterone may improve wellbeing in pre-
menopausal women but data are inconclusive
(Level 1, Grade B).
(d) Available data do not show an effect of tes-
tosterone on depressedmood (Level I, Grade B).
(6) Recommendations regarding the musculoskeletal
effects of testosterone
(a) Few studies have evaluated the musculoskel-
etal effects of testosterone.
(b) Of the studies that have reported musculo-
skeletal outcomes, the number of included
participants has been small, all participants
were taking concurrent estrogen therapy,
and no studies have been in women with
osteoporosis.
(c) The available data do not support an effect of
testosterone treatment on bone mineral den-
sity at the spine, total hip, or femoral neck at
12 months (Level I, Grade A).
(d) No statistically significant effect of testoster-
one administered in physiologic doses has
been demonstrated on lean body mass, total
body fat, or muscle strength (Level I, Grade
A).
(e) There is a need for clinical trials to evaluate the
impact of testosterone treatment on muscu-
loskeletal tissues (Expert Opinion).
(7) Recommendations regarding possible androgenic
side effects of testosterone therapy
(a) Systemic testosterone therapy for post-
menopausal women, in doses that approximate
physiological testosterone concentrations for
premenopausal women, is associated with mild
increases in acne and body/facial hair growth
in some women, but not with alopecia, clito-
romegaly, or voice change (Level I, Grade A).
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(8) Recommendations regarding testosterone therapy
and cardiovascular health
(a) Oral testosterone therapy is associated with
adverse lipid profiles with negative effects on
high-density lipoprotein-cholesterol and low-
density lipoprotein-cholesterol levels, and is
not recommended (Level I, Grade A).
(b) Studies of nonoral testosterone therapies
(percutaneous and injectable), in doses that
approximate physiological testosterone con-
centrations for premenopausal women, have
shown no statistically significant adverse ef-
fects on lipid profiles over the short term
(Level I, Grade A).
(c) Testosterone therapy has not been associated
with increases in blood pressure, blood glu-
cose, or HbA1c levels (Level I, Grade A).
(d) A nonsignificant trend for an increased risk of
deep venous thrombosis has been seen with
testosterone therapy; however, the role of
concurrent estrogen therapy in possible ve-
nous thrombosis risk cannot be excluded
(Level I, Grade A).
(e) Limited data preclude assessment of the effects
of testosterone therapy on myocardial infarc-
tion or death (Insufficient data).
( f) RCTs of testosterone therapy have excluded
women at high cardiometabolic disease risk;
most have included women taking concurrent
estrogen therapy, and all have been of relatively
short duration. Therefore, recommendations
regarding the effect of physiologic doses of
testosterone in postmenopausal women on car-
diovascular health are not generalizable to amore
“at-risk” population or to long-term therapy.
(9) Recommendations regarding testosterone therapy
and breast health
(a) Testosterone therapy does not increase mam-
mographic breast density (Level I, Grade A).
(b) Available data suggest that short-term trans-
dermal testosterone therapy does not impact
breast cancer risk (Level I, Grade A).
(c) Data from RCTs are insufficient to assess long-
term breast cancer risk (Insufficient data).
(d) There are no data to support the use of tes-
tosterone therapy to prevent breast cancer
(Insufficient data).
(e) Women with a prior diagnosis of breast
cancer were excluded from the randomized
trials for HSDD. Caution is recommended for
testosterone use in women with hormone-
sensitive breast cancer (Expert Opinion).
(10) Recommendations regarding testosterone ther-
apy and serious adverse events
(a) Testosterone therapy for postmenopausal
women, in doses that approximate physio-
logical testosterone concentrations for pre-
menopausal women, is not associated with
serious adverse events (Level I, Grade A).
(b) Because RCTs of testosterone therapy have
excluded women at high cardiometabolic
disease risk, and most have included women
taking concurrent estrogen therapy, recom-
mendation 10(a) is not generalizable to a
more “at-risk” population (Expert Opinion).
(c) Safety data for testosterone in physiologic
doses are not available beyond 24 months of
treatment (Level I, Grade A).order
III. Clinical care of postmenopausal women
(11) Recommendations regarding full assessment of
FSD before commencing testosterone therapy
(a) FSD including HSDD, FSAD, and orgasmic
disorder/dysfunction have multiple etiolo-
gies including biopsychosocial factors such
as neuroendocrine imbalance, physical ill
health or disease, interpersonal difficulties,
psychological distress, and sexually repres-
sive cultural or religious values (Grade C).
(b) Treatments should follow this biopsy-
chosocial model and include pharmaco-
logic options (hormone therapies and other
pharmacologic agents), psychotherapy, or
multimodal treatments that combine both
(17) (Grade B).
(12) Recommendations regarding current testoster-
one therapy and postmenopausal women
(a) The only evidence-based indication for the
use of testosterone in women is for the
treatment of postmenopausal women who
have been diagnosed as having HSDD after
formal biopsychosocial assessment (Level I,
Grade A).
(b) There is an unmet need for the provision
and approval of testosterone treatments
specific to women, formulated with the aim
of approximating physiological testosterone
concentrations for premenopausal women
(Expert Opinion).
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(c) Where an appropriate approved female
testosterone preparation is not available,
off-label, prescribing of an approved male
formulation is reasonable, provided hormone
concentrations are maintained in the physio-
logic female range (Expert Opinion).
(d) Compounded “bioidentical” testosterone ther-
apy cannot be recommended for the treatment
of HSDD because of the lack of evidence for
efficacy and safety, unless an authorized
equivalent preparation is not available (Expert
Opinion). In the absence of an available ap-
proved product, if a compounded product is
needed, the compounding pharmacy should be
compliant with purity of Active Pharmaceutical
Ingredients and Good Manufacturing Prac-
tice to meet industry standards for quality
and safety. Dosing should be limited to
achieving testosterone concentrations in the
physiologic premenopausal range.
(e) Use of any testosterone preparation that
results in supraphysiologic concentrations of
testosterone, including pellets and injections,
is not recommended (Expert Opinion).
( f) Should a trial of testosterone therapy be
given for HSDD, a baseline total testosterone
concentration should be measured before
commencement, with a repeat level 3–
6 weeks after treatment initiation (Level IIA,
Grade C).
(g) Patients should be monitored for their clin-
ical response to treatment and assessed for
signs of androgen excess with a serum total
testosterone level every 6 months, to screen
for overuse (Expert Opinion).
(h) If no benefit is experienced by 6 months,
treatment should be ceased (Level IB,
Grade C).
(13) Recommendations regarding other androgenic
preparations
(a) Systemic dehydroepiandrosterone is not as-
sociated with significant improvement in li-
bido or sexual function in postmenopausal
women with normal adrenal function and
cannot be recommended for women with
HSDD (18) (Level IA, Grade A).
(b) In the absence of vulvovaginal atrophy,
vaginal dehydroepiandrosterone has not been
tested and thus cannot be recommended for
treatment of HSDD (Expert Opinion).
(14) Recommendations regarding the design of future
trials of physiologically dosed testosterone (Ex-
pert Opinion for all)
(a) More adequately powered, double-blind
RCTs, without selection bias and with
consistent reporting of standardized out-
comes, are needed to comprehensively es-
tablish the benefits and risks of testosterone
therapy for women.
(b) For studies of testosterone and FSD:order
(i) Relief of the distress associated with
sexual dysfunction is a primary aim of
FSD treatment.
(ii) Presently, no questionnaire covers all
domains of female sexual function such
that a combination of domains from
different questionnaires should be used.
(iii) Satisfying sexual events should no longer
be used as a primary efficacy measure-
ment in clinical trials of women with
FSD.
(iv) A set of clearly defined core outcomes
needs to be established.
(v) There is a need for an instrument to
assess sexual function with the following
characteristics: general applicability; not
disease-specific; high discriminant val-
idity between women diagnosed with
FSD and sexually functional women;
validated, tomeasure FSD per se and as an
instrument to screen for and diagnose FSD
and demonstrating clinically meaningful
response to intervention; cover different
domains, with each domain comprising
several items; translated and back-
translated in a variety of languages, sat-
isfies the most stringent assessment to gain
approval by regulatory agencies.
(c) There is a need for adequately powered RCTs
of the effects of testosterone on the muscu-
loskeletal health of women with normal bone
mass, low bonemass, osteopenia/osteoporosis,
and sarcopenia, with outcomes including ver-
tebral and total hip and femoral neck bone
mineral density, trabecular bone score, serum
biomarkers, fracture risk, body composition,
and muscle strength.
(d) There is a need for adequately powered
RCTs of the effects of testosterone on cog-
nitive performance.
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(e) Studies must be undertaken to establish the
longer term cardiometabolic and breast
safety of testosterone therapy for women.
Summary and Key Messages
The international panel concluded the only evidence-
based indication for testosterone therapy for women
is for the treatment of HSDD, with available data
supporting a moderate therapeutic effect. There are in-
sufficient data to support the use of testosterone for the
treatment of any other symptom or clinical condition, or
for disease prevention.
Meta-analyses of the available data show no severe
adverse events during physiological testosterone use,
with the caveat that women at high cardiometabolic risk
were excluded from study populations. The safety of
long-term testosterone therapy has not been established.
It was considered of utmost importance that the di-
agnosis of HSDD involves a full clinical assessment and
that other factors contributing to FSD must be identified
and addressed before testosterone therapy is initiated
(10, 11). A blood total testosterone level should not be
used to diagnose HSDD. Treatment should only be with
formulations that achieve blood concentrations of tes-
tosterone that approximate premenopausal physiological
concentrations. Because no approved female product is
presently approved by a national regulatory body, male
formulations can be judiciously used in female doses and
blood testosterone concentrations must be monitored
regularly. The panel recommended against the use of
compounded testosterone.
The panel highlighted the pressing need for more
research into testosterone therapy for women and the
development and licensing of products indicated spe-
cifically for women.
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